Upcoming Events
We are excited to attend the BIO International Convention 2026, which brings together biotech innovators, investors, industry experts and media from around the world. Following the presentation of promising initial Phase 2 safety data for our lead candidate PRI-002 in Alzheimer’s disease and preclinical proof-of-concept data for our investigational compound PRI-101 in Parkinson’s Disease and in March, we are looking forward to discuss the next steps for our pipeline programs and broad potential of our detangler approach as a new disease-modifying option for neurodegenerative disorders.
Our CEO, Philipp Bürling, will be on site in San Diego from June 22-25, 2026, and is available for conversations. Feel free to reach out through the official partnering platform to schedule a meeting.
About Priavoid
Priavoid’s novel class of orally available all-D-peptide therapeutics detangle neurotoxic oligomer species to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders. We aim to establish clinical proof-of-concept through our lead program, PRI-002, which will complete a Phase 2 trial in Alzheimer’s disease in 2026. Priavoid has built a focused pipeline of detangler compounds that are non-immunogenic and reach their oligomer targets in the brain and inside the affected cells. Our goal is to develop disease-modifying therapies that address the underlying biology of neurodegeneration and drive meaningful clinical benefit for patients.